Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · Sep 2003
Randomized Controlled Trial Comparative Study Clinical TrialComparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide.
Inhaled, long-acting beta2-agonists or antileukotrienes are alternatives as add-on therapy for asthmatic children taking regular inhaled steroids. Any complementary effects would be relevant to the choice between these alternatives. Exhaled nitric oxide (FeNO) may reflect these effects. ⋯ The FeNO levels were significantly higher after salmeterol add-on treatment compared with both placebo and montelukast add-on treatment. Salmeterol significantly improved lung function (FEV1) compared with placebo and nonsignificantly compared with montelukast. Montelukast failed to reduce FeNO and improve lung function compared with placebo in this group of children taking regular budesonide, 400 microg.
-
Ann. Allergy Asthma Immunol. · Sep 2003
Randomized Controlled Trial Comparative Study Clinical TrialEfficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment.
We wanted to evaluate whether treatment with an inhaled corticosteroid and an inhaled long-acting beta2-agonist is more effective than an inhaled corticosteroid alone for patients using as-needed albuterol who are initiating maintenance treatment. ⋯ Treatment with FSC in a CFC-free MDI is more effective than FP or salmeterol alone in asthma patients who are symptomatic taking short-acting beta2-agonists alone.
-
Ann. Allergy Asthma Immunol. · Aug 2003
Randomized Controlled Trial Multicenter Study Clinical TrialOmalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Treatment with omalizumab, an anti-IgE antibody, improves symptoms and quality of life in patients with seasonal allergic rhinitis but has not previously been investigated in patients with perennial symptoms. ⋯ Omalizumab was safe and well tolerated in the treatment of patients with PAR, providing effective control of symptoms and improved RQoL while simultaneously minimizing reliance on rescue antihistamines.
-
Ann. Allergy Asthma Immunol. · Aug 2003
Randomized Controlled Trial Multicenter Study Clinical TrialOmalizumab is effective in the long-term control of severe allergic asthma.
Previous reports show that addition of omalizumab to standard therapy reduces asthma exacerbations and simultaneously decreases use of inhaled corticosteroids (ICSs) and rescue medication in patients with allergic asthma. ⋯ These results indicate that omalizumab is effective in the long-term control of severe allergic asthma.
-
Ann. Allergy Asthma Immunol. · Aug 2003
Randomized Controlled Trial Multicenter Study Clinical TrialEvaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
To evaluate the long-term effects of the anti-IgE antibody omalizumab in children with asthma. ⋯ Long-term treatment with omalizumab is safe and well tolerated in children with allergic asthma.